Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies Levels in Chronic Viral Hepatitis (B&C)
Journal of Advances in Medicine and Medical Research,
Background: Extrahepatic manifestations is a relatively common feature in patients with chronic hepatitis C virus infection. Among the different clinical disorders associated with HCV infection, articular involvement is a frequent complication, and the clinical picture of HCV related arthropathy varies widely. In particular, monoarticular or oligoarticular involvement affects larger joints and is typically associated with mixed cryoglobulinemia, whereas symmetric polyarthritis associated with HCV infection frequently displays a rheumatoid arthritis like clinical picture which can be clinically indistinguishable from RA itself. This study aimed to evaluate level of Rheumatoid Factor and anti-CCP level in chronic viral hepatitis B&C.
Patients and methods: Thirty patients with rheumatoid arthritis, thirty patients with chronic hepatitis C virus and thirty patients with chronic hepatitis B virus were selected to perform this study and they were compared to thirty normal subjects as a reference group.
Results: There was significant difference between the hemoglobin in the four groups. As regard Rheumatoid Factor there was significant difference between the studied groups. As regard Anti-CCP, there was significant difference between the studied groups. There was also significant difference between the four groups according to level of positivity. Finally, our study shows clinically significant positive correlation between RF as well as anti CCP titer and both HBV DNA and HCV RNA viral levels.
Conclusions: Rheumatoid factor was found with considerable percentage in chronic HBV & HCV patients without musculoskeletal manifestations. Anti-CCP can be detected with low positivity in chronic HBV&HCV patients even without arthritic manifestations. There is a significant positive correlation between RF titre and HBV DNA& HCV RNA in chronic hepatitis patients. There is a significant positive correlation between anti-CCP and HBV DNA& HCV RNA in chronic hepatitis patients. Chronic HBV & HCV can be considered and investigated in patients with positive RF and/or anti CCP without arthritic manifestations.
- Rheumatoid factor
- anti-cyclic citrullinated peptide antibodies levels
- chronic viral hepatitis
How to Cite
Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. Hemodialysis International. 2018;22:S8-S21.
Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study. J Infect Dis. 2011; 206:469–477.
Corman S, Elbasha EH, Michalopoulos SN, et al. Cost-utility of elbasvir/ grazoprevir in patients with chronic hepatitis C genotype 1 infection. Value in Health. 2017;20(8):1110-1120.
Alazawi W, Cunningham M, Dearden J, et al. Systematic review: Outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment. Pharmacol. Ther. 2010;32:344–355.
Hong TP, Gow P, Fink M, et al. Novel population based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatology. 2016;63:1205–1212.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-1555.
Vlachogiannakos J, Papatheodoridis GV. Hepatitis B: Who and when to treat?. Liver International. 2018;38:71-78.
Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden disease study 2013. Lancet. 2016;388 :1081-1088.
Gottenberg JE, Mignot S, Nicaise-Rolland, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Annals of the Rheumatic Diseases. 2005; 64 (1):114-117.
Ingegnoli F, Galbiati V, Zeni S, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol. 2007;26 (4):510–514.
Takasaki Y, Yamanaka K, Takasaki C, et al. Anticyclic-citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol. 2004;14 (5):367–375.
Lima İU, Santiago M. Antibodies against cyclic citrullinated peptides in infectious diseases: A systematic review. Clin Rheumatol. 2010;29:1345–1351.
Kappus MR, Sterling RK. Extrahepatic manifestations of acute hepatitis B virus infection. Gastroenterol Hepatol (NY). 2013;9(2):123– 126.
Buzgan T, Karahocagil MK, Irmak H, et al. Clinical manifestations and complications in 1028 cases of brucellosis: A retrospective evaluation and review of the literature. Int J Infect Dis. 2010;14(6):469–478.
Zengin O, Yıldız H, Demir ZH, et al. Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies with hepatitis B and hepatitis C infection. Advances in clinical and experimental medicine: official organ Wroclaw Medical University. 2017;26(6):987-990.
Sargin G, Kandemir A. Clinical utility of anti-cyclic citrullinated peptid and rheumatoid factor in chronic hepatitis B virus infection. Indian Journal of Rheumatology. 2018;13(4):229.
Örge E, Çefle A, Yazici A, et al. The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. Rheumatology International. 2010;30(4):485-488.
Tamer WM, Eltoukhy MS. Predictive clinical value of rheumatoid factor and anti-citrullinated protein antibodies as diagnostic tools in cases with non-arthritic chronic hepatitis C Viral Disease. United Journal of Internal Medicine. 2019; 1(1):1-4.
Liu FC, Chao YC, Hou TY, et al. Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia. Clinical Rheumatology. 2008;27(4):463-467.
Lee SI, Yoo WH, Yun HJ, et al. Absence of antibody to cyclic citrullinated peptide in sera of non-arthritic patients with chronic hepatitis B virus infection. Clinical Rheumatology. 2007;26(7):1079-1082.
Bombardier C, Laine L, Burgos-Vargas R, et al. Response to expression of concern regarding VIGOR study. New England J Med. 2006;354(11):1196-9.
Hussein MS, Abdel Ghany SEA, Elashkar DS, et al. Anti-CCP hs (high sensitive) in Egyptian rheumatoid arthritis patients associated with chronic hepatitis C virus infection. The Egyptian Rheumatologist; 2016;38(1):15-20.
Sene D, Ghillani-Dalbin P, Limal N, et al. Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjögren’s syndrome. Annals of the Rheumatic Diseases. 2006;65(3):394- 397.
Wener MH, Hutchinson K, Morishima C, et al. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2004;50(7):2305-2308.
Abstract View: 68 times
PDF Download: 26 times